Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • S16 Ep52: Medical Crossfire: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application
  • Clinical Data

S16 Ep52: Medical Crossfire: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application

OncLive Podcast

In this podcast, experts April K.S.

Clinical DataOncologyRead full story

pharminent April 15, 2026

OncLive Podcast

In this podcast, experts April K.S.

Clinical DataOncologyRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Amazon launches AI drug discovery platform
Next: Scientists issue call to arms over antifungal resistance

Related Stories

  • Clinical Data

Boehringer advances duo for aggressive cancers into phase 3

pharminent June 22, 2026
  • Clinical Data

Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short

pharminent June 17, 2026
  • Clinical Data

EHA26: BMS touts positive multiple myeloma data for two pipeline candidates

pharminent June 17, 2026

You May Have Missed

  • News

pharminent June 22, 2026
sample_feature_2026-06-22
  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.